ctDNA test for guiding endometrial cancer treatment decisions
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or recurrent endometrial cancer (stage III with remaining disease, stage IV, or cancer that came back after initial treatment).
- Your tumor has a feature called MMR deficiency (MMR-D) or high microsatellite instability (MSI-H), which makes it more likely to respond to immunotherapy.
- You are able to receive standard chemotherapy combined with an immunotherapy drug (PD-1 or PD-L1 inhibitor) as part of your care.
- You have not previously had treatment with PD-1, PD-L1, or CTLA-4 inhibitors (except for a small group of patients already on this treatment without progression).
- You are 18 or older and not pregnant or nursing.
- If you had brain metastases, they must have been treated and stable on a recent scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a ctDNA blood test along with standard CT scans can help guide treatment decisions for people with incurable metastatic gastrointestinal cancer. It may help doctors decide sooner whether a treatment is working.
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
This study looks at whether a blood test that finds tumor DNA can help doctors choose the best treatment for rectal cancer, possibly allowing some patients to avoid surgery. It tests different chemotherapy and radiation combinations to see if the cancer disappears completely.
This trial uses a blood test to track tumor DNA in patients with HPV-related cervical or anal cancer. It aims to see if this test can detect early signs of recurrence after radiation therapy, helping guide follow-up care.
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.